Nanjing Hicin Pharmaceutical Co., Ltd. (SHE:300584)

China · Delayed Price · Currency is CNY

32.08

+5.35 (20.01%)

Oct 23, 2026, 3:04 PM CST

Market Cap	3.85B -42.5%
Revenue (ttm)	814.80M +32.4%
Net Income	71.64M +60.0%
EPS	0.60 +60.0%
Shares Out	120.00M
PE Ratio	53.73
Forward PE	n/a
Dividend	0.10 (0.31%)
Ex-Dividend Date	Jun 25, 2026

Volume	9,553,531
Open	28.68
Previous Close	26.73
Day's Range	28.56 - 32.08
52-Week Range	26.29 - 73.40
Beta	0.07
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 23, 2026

About SHE:300584

Nanjing Hicin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of chemical preparations, APIs, and intermediates. The company’s products include landiolol hydrochloride, rivaroxaban, tigecycline, torasemide, cefuroxime sodium, ceftriaxone hydrochloride, ganciclovir sodium, adenosine monophosphate, and adenosine monophosphate for injection; voglibose tablets, lansoprazole enteric-coated tablets, amlodipine besylate tablets, and glucosamine sulfate effervescent tablets; and raw m... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2003

Employees 553

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 300584

Full Company Profile

Financial Performance

In 2025, SHE:300584's revenue was 671.05 million, an increase of 33.05% compared to the previous year's 504.36 million. Earnings were 42.06 million, an increase of 4.58%.

Financial Statements